We serve Chemical Name:3-(Pyridin-3-Yl)-4,5-Dihydro-1,2,4-Oxadiazol-5-One CAS:1198-99-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:3-(Pyridin-3-Yl)-4,5-Dihydro-1,2,4-Oxadiazol-5-One
CAS.NO:1198-99-8
Synonyms:3-(Pyridin-3-Yl)-4,5-Dihydro-1,2,4-Oxadiazol-5-One
Molecular Formula:C7H5N3O2
Molecular Weight:163.13300
HS Code:2934999090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:267.9ºC at 760mmHg
Density:1.53g/cm3
Index of Refraction:1.702
PSA:71.78000
Exact Mass:163.03800
LogP:0.42490
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 3-(Pyridin-3-Yl)-4,5-Dihydro-1,2,4-Oxadiazol-5-One chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-(Pyridin-3-Yl)-4,5-Dihydro-1,2,4-Oxadiazol-5-One physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-(Pyridin-3-Yl)-4,5-Dihydro-1,2,4-Oxadiazol-5-One Use and application,3-(Pyridin-3-Yl)-4,5-Dihydro-1,2,4-Oxadiazol-5-One technical grade,usp/ep/jp grade.
Related News: As one analyst noted during the call, more than $1 billion in annual sales from older AZ products are now exposed to China’s volume-based procurement (VBP) initiative, a price-cutting program that targets off-patent drugs. 2-Propen-1-one, 1-(3-chlorophenyl)-3-[4-(dimethylamino)phenyl]- manufacturers Officials did, however, acknowledge that there’s growing evidence an extra jab may enhance the antibody response in immunocompromised people. Some small studies suggest up to 50% of people with no antibody response after the authorized regimen of two mRNA jabs developed a response after an additional dose, said CDC’s Sara Oliver, M.D. potassium,1-amino-4-[3-[2-(diethylamino)ethylsulfonyl]anilino]-9,10-dioxoanthracene-2-sulfonate suppliers McNamara joined GSK from Novartis in 2015 when the two companies combined their OTC portfolios into a joint venture managed by GSK. He became head of GSK consumer health in 2016, taking the baton from Walmsley as she moved up the command chain to CEO of the entire group. Novartis in 2018 backed out of the collab, and after taking full control of the venture, GSK formed a new JV with Pfizer in 2019. (3S)-Tetrahydro-3-furanyl N-(1S,2R)-1-benzyl-2-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](5-oxohexyl)amino]-propylcarbamate vendor & factory.
